Full-Time

CRM Analyst

Posted on 10/1/2025

Charles River Associates (CRA)

Charles River Associates (CRA)

1,001-5,000 employees

Global consulting delivering economic, litigation analysis

Compensation Overview

$75k - $85k/yr

+ Bonus + Equity Grants

Boston, MA, USA + 3 more

More locations: Toronto, ON, Canada | Chicago, IL, USA | New York, NY, USA

Hybrid

Hybrid role; requires 3-4 days per week in-office, with days coordinated with the team.

Category
Growth & Marketing (1)
Required Skills
Branding/Brand Strategy
Social Media
Data Analysis
Requirements
  • 2-4 years of experience with CRM systems and marketing automation platforms
  • Strong technical skills in data management, system configuration, and workflow design
  • Experience with CRM migrations and system implementations
  • Proficiency in data analysis and basic reporting/analytics tools
  • Detail-oriented approach with strong organizational and project management skills
  • Collaborative mindset with ability to work effectively across functional teams
Responsibilities
  • Participate in the migration to our new CRM and marketing automation platform (Intapp Deal cloud and Dispatch), ensuring seamless data transition and system functionality
  • Build and maintain accurate client and prospect databases that support targeted content distribution strategies
  • Configure CRM workflows and processes that align with CRA's brand strategy and business development objectives
  • Ensure data integrity and implement quality control measures to maintain system effectiveness
  • Develop and manage workflows for distributing thought leadership content to targeted client segments
  • Track basic engagement metrics to identify where market demand is being generated and through which clients
  • Create reporting frameworks that measure content campaign effectiveness and client interaction patterns
  • Support cross-functional teams with data insights that inform content strategy and client outreach
  • Support the broader marketing team with data-driven insights for strategic decision making
  • Coordinate with other marketing functions to ensure CRM data supports activities (i.e. events, social media)
Desired Qualifications
  • Experience in professional services or B2B marketing environments
  • Familiarity with content marketing measurement and campaign tracking
  • Knowledge of marketing automation best practices
  • Understanding of sales and business development processes
Charles River Associates (CRA)

Charles River Associates (CRA)

View

CRA is a global consulting firm that offers specialized services in litigation, regulatory, financial, and management consulting. It uses economic and financial analysis, modeling, and expert testimony to support clients in disputes, regulatory matters, and strategic decisions. The firm differentiates itself through rigorous quantitative analysis, industry expertise, and a worldwide network that delivers tailored, objective insights. Its goal is to help clients achieve favorable outcomes by providing precise analyses, clear testimony, and practical recommendations.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

City of Brussels, Belgium

Founded

1978

Simplify Jobs

Simplify's Take

What believers are saying

  • Record Q1 2026 revenue of $201M with 10.5% growth; eight practices expanding.
  • Hitesh Makhija hire strengthens antitrust capabilities amid intensifying M&A and regulatory activity.
  • Stock trades 55% below fair value at $139; analysts maintain $252 price target.

What critics are saying

  • Q1 earnings miss 15% triggers 12% stock drop; growth slows to 3.2% annually.
  • Cyclical M&A and regulatory deal flow collapse eliminates core revenue drivers entirely.
  • Talent poaching drains expertise; Makhija's prior departure signals retention vulnerability in high-margin practices.

What makes Charles River Associates (CRA) unique

  • Founded by Harvard and MIT professors; rigorous analytical heritage differentiates from competitors.
  • Serves 88% of Fortune 100 and 98% of Am Law 100 with deep client relationships.
  • Specialized expertise in antitrust, IP, transfer pricing, and forensic finance commands premium fees.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Wellness Program

Flexible Work Hours

Remote Work Options

Professional Development Budget

Company News

Business Wire
Apr 2nd, 2026
CRA appoints Christine Detrick as Lead Independent Director as William Concannon retires after 26 years

Charles River Associates has announced that Director Christine Detrick will become Lead Independent Director, effective 16th July 2026, following the planned retirement of current Lead Independent Director William Concannon. Concannon's retirement will take effect at CRA's 2026 Annual Meeting of Shareholders. Concannon has served on CRA's board since 2000 and as Lead Director since 2020. He informed the board of his decision to retire to spend more time with family. Detrick has been a board member since 2020 and currently chairs the Nominating and Corporate Governance Committee. CRA is a global consulting firm specialising in economic, financial and management consulting services, headquartered in Boston with offices worldwide.

The Pharma Letter
Mar 17th, 2026
Invest in European pharma to reap dividends, report says.

Invest in European pharma to reap dividends, report says. 17 March 2026 The European Federation of Pharmaceutical Industries and Associations (EFPIA) has highlighted the findings from a report by consultants Charles River Associates (Nasdaq: CRAI) that the trade group had commissioned. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK 16 March 2026 9 March 2026 16 February 2026 Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news 17 March 2026 Company spotlight. A private biotechnology company developing synthetic macrocyclic peptide therapeutics designed to target historically "undruggable" proteins. Unnatural Products focuses on bridging the gap between small molecules and biologics through orally available, cell-permeable macrocycles. More features in pharmaceutical. 17 March 2026

Yahoo Finance
Mar 9th, 2026
CRA International raises 2026 revenue outlook to $805M, maintains $0.57 dividend

CRA International has raised its 2026 revenue guidance to $785 million to $805 million in constant currency, signalling expectations for higher consulting demand. The company reported fourth-quarter 2025 revenue of $196.96 million and full-year 2025 revenue of $751.58 million, with net income of $54.78 million. The firm declared a quarterly dividend of $0.57 per share, payable on 20 March 2026. This marks continued cash returns to shareholders despite net debt of approximately $100.6 million. CRA's investment narrative remains tied to consulting demand driven by global mergers and acquisitions and regulatory activity. The key risk is demand cyclicality, particularly if dealmaking or enforcement activity slows sharply. Community fair value estimates for the stock range from $252 to $333 per share.

Business Wire
Mar 4th, 2026
CRA adds renowned digital economy expert Dr Steven Tadelis to strengthen antitrust testifying capabilities

Charles River Associates has appointed Dr Steven Tadelis, a professor at UC Berkeley's Haas School of Business, as a senior consultant to its Antitrust & Competition Economics Practice. Dr Tadelis specialises in e-commerce and internet economics, with research covering digital advertising effectiveness, online marketplace reputation systems and algorithmic pricing. Dr Tadelis has provided expert economic testimony in major US and Canadian litigation cases involving digital markets and participated in Federal Trade Commission hearings. He previously held senior roles at eBay Research Labs and Amazon, serving as vice president of economics and market design. The appointment strengthens CRA's testifying capabilities in antitrust and consumer protection cases involving digital platforms and internet economics.

Yahoo Finance
Feb 27th, 2026
Charles River Associates hits record annual revenue with Q4 at $197M, beats consensus despite EPS miss

Charles River Associates reported fourth-quarter revenue of $196.96 million, beating consensus estimates of $190.54 million, though earnings per share of $2.06 fell slightly short of the $2.07 consensus. The company achieved its eighth consecutive year of record annual revenue. Revenue grew 11.6% year-over-year in the fourth quarter, driven by double-digit growth in four practices: Antitrust & Competition Economics, Energy, Forensic Services, and Labor & Employment. Life Sciences and Risk, Investigations & Analytics also expanded. Geographically, North American operations increased 9.4% whilst international operations grew 21.9%. CEO Paul Maleh said strong top-line growth drove record profitability, with net income, earnings per diluted share and EBITDA each reaching new annual highs.

INACTIVE